ArticleInternational journal of biological sciences2026
Loss of Alkbh5 enhances AT2 cell differentiation and alveolar repair across diverse injury models via m
Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efficient regeneration of the alveolar epithelium is essential for restoring lung function after injury, yet the mechanisms that govern alveolar type II cell (AT2) behavior remain insufficiently defined. Here, we identify the m⁶A RNA demethylase Alkbh5 as a pivotal regulator of AT2 cell activation and lineage progression. Conditional deletion of Alkbh5 in AT2 cells markedly enhances their proliferation and differentiation across diverse lung injury contexts-including fibrotic (bleomycin), inflammatory (LPS), mechanical (pneumonectomy), and oxidative (BHT) insults. Loss of Alkbh5 increases m⁶A modification on Amphiregulin (Areg) transcripts, stabilizing its mRNA and elevating Areg expression specifically within transitional AT2 populations. The resulting amplification of EGFR signaling drives accelerated AT2-to-AT1 differentiation and epithelial repair. Supplementation of recombinant Areg phenocopies the regenerative effects of Alkbh5 deletion, whereas Areg neutralization abrogates these responses, establishing Areg as a key downstream effector of Alkbh5. Importantly, ALKBH5 ablation or pharmacologic inhibition in human ESC-derived alveolar organoids similarly promote proliferation, differentiation, and AREG upregulation, demonstrating evolutionary conservation of this regulatory axis. Together, our findings reveal an Alkbh5-Areg-EGFR circuit that orchestrates alveolar epithelial regeneration and suggest new therapeutic opportunities for enhancing lung repair following injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.